SCHEMBL268468

SCHEMBL268468

CCN(CC)CCN(C)Cc1cccc(C(=O)Nc2ccc(N3CCCCC3)cc2C(=O)N/N=C/c2ccc(C)c(C)c2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC34A2 O95436 3/20 0.42
ALDH1A1 P00352 6/20 0.39
MAPT P10636 7/20 0.37
KDM4E B2RXH2 7/20 0.37
SLC34A1 Q06495 1/20 0.37
SLC34A3 Q8N130 1/20 0.37
SLC20A1 Q8WUM9 1/20 0.37
GFER P55789 1/20 0.37
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
RAB9A P51151 3/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
PKM P14618 2/20 0.36
LMNA P02545 1/20 0.35
HPGD P15428 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL268469 1.00 SLC34A2 (0.42) SLC34A2ALDH1A1MAPTKDM4ESLC34A1
SCHEMBL268223 0.99 SLC34A2 (0.42) SLC34A2ALDH1A1MAPTKDM4ESLC34A1
SCHEMBL268224 0.99 SLC34A2 (0.42) SLC34A2ALDH1A1MAPTKDM4ESLC34A1
SCHEMBL267758 0.95 ALDH1A1 (0.40) SLC34A2ALDH1A1MAPTKDM4ESLC34A1
SCHEMBL267757 0.95 ALDH1A1 (0.40) SLC34A2ALDH1A1MAPTKDM4ESLC34A1
SCHEMBL266768 0.93 ALDH1A1 (0.48) SLC34A2ALDH1A1MAPTKDM4ERAB9A
SCHEMBL266767 0.93 ALDH1A1 (0.48) SLC34A2ALDH1A1MAPTKDM4ERAB9A
SCHEMBL268630 0.93 ALDH1A1 (0.42) SLC34A2ALDH1A1MAPTKDM4ESLC34A1
SCHEMBL268631 0.93 ALDH1A1 (0.42) SLC34A2ALDH1A1MAPTKDM4ESLC34A1
SCHEMBL267290 0.91 ALDH1A1 (0.43) SLC34A2ALDH1A1MAPTKDM4ESLC34A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 SLC34A2 6/4885ALDH1A1 3022/4885MAPT 4195/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 SLC34A2 2/4885ALDH1A1 2872/4885MAPT 4648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.